Berenberg Bank set a €68.00 ($80.95) target price on MorphoSys AG (ETR:MOR) in a report released on Tuesday morning. The firm currently has a buy rating on the stock.

Several other research analysts have also commented on MOR. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price target on shares of MorphoSys AG and gave the company a neutral rating in a report on Friday, August 4th. Deutsche Bank AG set a €90.00 ($107.14) price target on shares of MorphoSys AG and gave the company a buy rating in a report on Monday, August 7th. Commerzbank Ag set a €76.00 ($90.48) price target on shares of MorphoSys AG and gave the company a buy rating in a report on Friday, July 14th. J P Morgan Chase & Co restated a neutral rating on shares of MorphoSys AG in a report on Monday, July 17th. Finally, Independent Research GmbH set a €77.00 ($91.67) price target on shares of MorphoSys AG and gave the company a buy rating in a report on Monday, August 7th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of €70.38 ($83.78).

MorphoSys AG (ETR:MOR) opened at 68.399 on Tuesday. The company has a 50 day moving average of €60.74 and a 200-day moving average of €59.75. The firm’s market cap is €1.98 billion. MorphoSys AG has a one year low of €35.72 and a one year high of €70.90.

WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/morphosys-ag-mor-given-a-68-00-price-target-by-berenberg-bank-analysts/1575084.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.